Table 3.
Overview of studies on treatment with androgen deprivation therapy for patients with androgen receptor‐positive salivary duct carcinoma
| Author | No. of patients | ADT | Results | ||||
|---|---|---|---|---|---|---|---|
| CR (%) | PR (%) | Stable disease (%) | PD (%) | Clinical benefit, % | |||
| Current papera | 35b | Bicalutamide + /‐ LHRH analogue | 0 | 6 (18) | 11 (32) | 17 (50) | 50 |
| Jaspers et al8 | 10 | Bicalutamide + /‐ LHRH analogue | 0 | 2 (20) | 3 (30) | 5 (50) | 50 |
| Locati et al14 | 8 | Bicalutamide or cyproterone acetate (1 patient) + LHRH analogue | 2 (25) | 2 (25) | 3 (38) | 1 (13) | 87 |
| Yajima et al15 | 8 | LHRH analogue | 0 | 2 (25) | 3 (38) | 3 (38) | 63 |
Abbreviations: ADT, androgen deprivation therapy; CR, complete response; LHRH, luteinizing hormone‐releasing hormone; PD, progressive disease; PR, partial response.
a
Ten patients described in the current article were published before.8
b
There were 34 evaluable patients.
Clinical benefit is CR + PR + stable disease.